-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Ravidasvir hydrochloride
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1303533-81-42d.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1303533-81-4 |
| Description | Avidasvir is a second-generation Hepatitis C virus NS 5 protein inhibitor. In Sep 2016, Phase-II/III clinical trials in Hepatitis C in Malaysia was on-going. |
Product Information
| Synonyms | Ravidasvir dihydrochloride;1303533-81-4;Ravidasvir hydrochloride;PPI-668;Ravidasvir HCl;Ravidasvir hydrochloride [USAN];Ravidasvir (hydrochloride);BL-238630 DIHYDROCHLORIDE;BI 238630 CL2;BI-238630-CL2;HWN7376681;Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester, hydrochloride (1:2);Methyl N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamate dihydrochloride;methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride;Ravidasvir hydrochloride (USAN);UNII-HWN7376681;CHEMBL3545312;BCP20103;MFCD32705191;AKOS037648659;Ravidasvir hydrochloride (PPI-668)?;RAVIDASVIR HYDROCHLORIDE [WHO-DD];BS-15113;HY-124191;CS-0085820;D12745;D81555;Q27280134;Methyl N-[(1S)-1-({(2S)-2-[5-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-1H-imidazol-4-yl}naphthalen-2-yl)-1H-benzimidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate dihydrochloride;MethylN-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamatedihydrochloride; |
| IUPAC Name | methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride |
| Molecular Weight | 835.82 |
| Molecular Formula | C42H52Cl2N8O6 |
| Canonical SMILES | COC(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C2=NC3=CC=C(C4=CC5=C(C=C(C6=CN=C([C@H]7N(CCC7)C([C@H](C(C)C)NC(OC)=O)=O)N6)C=C5)C=C4)C=C3N2)=O)=O.Cl.Cl |
| InChI | InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1 |
| InChIKey | JYLMWUZJMRNMDA-SPRBZRACSA-N |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Powder |
| Application | Hepatitis C |
| Shelf Life | 2 month in rt, long time |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |